1. 首页
  2. ›Novo Nordisk CagriSema Weight Loss Data: Early Responders Achieve 25.4% Weight Loss at 68 Weeks

Novo Nordisk CagriSema Weight Loss Data: Early Responders Achieve 25.4% Weight Loss at 68 Weeks

N
nashnova research
·2026-11-15发布·阅读约 9 分钟

Novo Nordisk presented two exploratory analyses from its REDEFINE 1 Phase III trial at ObesityWeek 2026 — early responders on CagriSema lost 25.4% of body weight by week 68, but GI side effects hit nearly 80%. The FDA decision is expected in Q4 2026.

01

Where does the "25.4%" come from?

•
67.8% of CagriSema subjects lost 5% or more of body weight by week 8 — qualifying them as "early responders."
•
By week 68, early responders averaged 25.4% weight loss; slower responders averaged 17.8%.
•
This means → the drug does not work equally for everyone: nearly seven in ten responded fast and lost more, but the remaining three in ten saw a markedly smaller effect.
•
Novo Nordisk cautioned that these figures come from on-treatment measurements and should not guide clinical decisions — in plain terms = this is a post-hoc data cut, not a pre-specified endpoint the trial was designed to prove.
02

Beyond weight, did daily life improve?

•
73.1% of the CagriSema group reported meaningful improvement in daily physical activity, versus 49.1% on placebo.
•
For self-esteem and social comfort, 69% in the CagriSema group reported improvement, versus 42.1% on placebo.
•
This means → the gap between drug and placebo is roughly 20–27 percentage points, with measurable gains on both physical and psychological dimensions.
•
These estimates assume all subjects completed treatment as planned — real-world dropout would likely narrow the gap.
03

How serious are the side effects?

•
79.6% of the CagriSema group experienced gastrointestinal adverse events (nausea, diarrhea, etc.), versus 39.9% on placebo.
•
In plain terms = roughly four out of every five people on the drug had GI discomfort — a familiar weak spot across today's weight-loss medications.
•
Discontinuation due to side effects: 5.9% for CagriSema, 3.5% for placebo — a modest difference, meaning most patients stayed on treatment.
•
This reflects a core tension in the weight-loss drug race: the more potent the drug, the higher the GI side-effect rate tends to be — regulators and the market are both watching where that line falls.
04

What exactly is CagriSema?

•
CagriSema is a once-weekly injection combining two active ingredients: cagrilintide — which mimics an appetite-suppressing hormone — and semaglutide, the core compound behind Ozempic and Wegovy.
•
REDEFINE 1 enrolled adults with obesity or overweight plus related health conditions, but without type 2 diabetes.
•
This means → the drug targets a "pure weight-loss" population, not diabetes patients who also lose weight — a more focused market position than existing products.
05

How far is it from market?

•
CagriSema is not yet approved in the U.S. The FDA decision is expected in Q4 2026.
•
This means → the clinical data are on the table; the key question now is whether the FDA considers them sufficient for approval.
•
Both analyses released this time are exploratory — not the confirmatory evidence required for regulatory clearance. In plain terms = they can boost market confidence, but they do not directly determine the approval outcome.

市场有风险,内容仅供研究参考,不构成投资建议。

相关标的

3
  • Novo NordiskNVO.US+2.4%

    Central subject of the event; CagriSema weight loss data directly impacts its Q4 2026 approval expectations and obesity pipeline valuation.

  • Eli LillyLLY.US+1.3%

    Direct competitor in the GLP-1 weight loss space; the strength of CagriSema data directly affects tirzepatide market share expectations.

  • Viking TherapeuticsVKTX.US+5.9%

    Biotech developing GLP-1/GIP dual-target weight loss drugs; CagriSema data reshapes competitive landscape expectations for obesity therapeutics.